APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immunotherapeutic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Immunotherapeutic Drugs Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchImmunotherapeutic Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Immunotherapeutic Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Immunotherapeutic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immunotherapeutic Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Immunotherapeutic Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Immunotherapeutic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Immunotherapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immunotherapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immunotherapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Immunotherapeutic Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Immunotherapeutic Drugs market include Johnson & Johnson, Novartis, Merck, Roche, ELI Lilly, GlaxoSmithKline, Amgen, AbbVie and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Immunotherapeutic Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immunotherapeutic Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immunotherapeutic Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Immunotherapeutic Drugs market.

Immunotherapeutic Drugs Segment by Company

Johnson & Johnson

Novartis

Merck

Roche

ELI Lilly

GlaxoSmithKline

Amgen

AbbVie

AstraZeneca

Bristol-Mysers Squibb

Immunotherapeutic Drugs Segment by Type

Monoclonal Antibody

Interferon

Checkpoint Inhibitor

Vaccines

Immunotherapeutic Drugs Segment by Application

Hospitals

Clinics

Other

Immunotherapeutic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Immunotherapeutic Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Immunotherapeutic Drugs key companies, revenue, market share, and recent developments.

3. To split the Immunotherapeutic Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Immunotherapeutic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Immunotherapeutic Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Immunotherapeutic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immunotherapeutic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immunotherapeutic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immunotherapeutic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immunotherapeutic Drugs industry.

Chapter 3: Detailed analysis of Immunotherapeutic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Immunotherapeutic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Immunotherapeutic Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Immunotherapeutic Drugs Industry Trends Table 2. Immunotherapeutic Drugs Industry Drivers Table 3. Immunotherapeutic Drugs Industry Opportunities and Challenges Table 4. Immunotherapeutic Drugs Industry Restraints Table 5. Global Immunotherapeutic Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Immunotherapeutic Drugs Revenue Share by Company (2021-2026) Table 7. Global Immunotherapeutic Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Immunotherapeutic Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Immunotherapeutic Drugs Company, Product Type & Application Table 10. Global Immunotherapeutic Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Immunotherapeutic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Monoclonal Antibody Table 15. Significant Companies of Interferon Table 16. Significant Companies of Checkpoint Inhibitor Table 17. Significant Companies of Vaccines Table 18. Global Immunotherapeutic Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Immunotherapeutic Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Immunotherapeutic Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Immunotherapeutic Drugs Sales Value Share by Type (2021-2026) Table 22. Global Immunotherapeutic Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Clinics Table 25. Significant Companies of Other Table 26. Global Immunotherapeutic Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Immunotherapeutic Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Immunotherapeutic Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Immunotherapeutic Drugs Sales Value Share by Application (2021-2026) Table 30. Global Immunotherapeutic Drugs Sales Value Share by Application (2027-2032) Table 31. Global Immunotherapeutic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Immunotherapeutic Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Immunotherapeutic Drugs Sales Value Share by Region (2021-2026) Table 34. Global Immunotherapeutic Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Immunotherapeutic Drugs Sales Value Share by Region (2027-2032) Table 36. Global Immunotherapeutic Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Immunotherapeutic Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Immunotherapeutic Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Immunotherapeutic Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Immunotherapeutic Drugs Sales Value Market Share by Country (2027-2032) Table 41. Johnson & Johnson Company Information Table 42. Johnson & Johnson Business Overview Table 43. Johnson & Johnson Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Johnson & Johnson Immunotherapeutic Drugs Product Portfolio Table 45. Johnson & Johnson Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Novartis Immunotherapeutic Drugs Product Portfolio Table 50. Novartis Recent Development Table 51. Merck Company Information Table 52. Merck Business Overview Table 53. Merck Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Merck Immunotherapeutic Drugs Product Portfolio Table 55. Merck Recent Development Table 56. Roche Company Information Table 57. Roche Business Overview Table 58. Roche Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Roche Immunotherapeutic Drugs Product Portfolio Table 60. Roche Recent Development Table 61. ELI Lilly Company Information Table 62. ELI Lilly Business Overview Table 63. ELI Lilly Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. ELI Lilly Immunotherapeutic Drugs Product Portfolio Table 65. ELI Lilly Recent Development Table 66. GlaxoSmithKline Company Information Table 67. GlaxoSmithKline Business Overview Table 68. GlaxoSmithKline Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. GlaxoSmithKline Immunotherapeutic Drugs Product Portfolio Table 70. GlaxoSmithKline Recent Development Table 71. Amgen Company Information Table 72. Amgen Business Overview Table 73. Amgen Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Amgen Immunotherapeutic Drugs Product Portfolio Table 75. Amgen Recent Development Table 76. AbbVie Company Information Table 77. AbbVie Business Overview Table 78. AbbVie Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. AbbVie Immunotherapeutic Drugs Product Portfolio Table 80. AbbVie Recent Development Table 81. AstraZeneca Company Information Table 82. AstraZeneca Business Overview Table 83. AstraZeneca Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. AstraZeneca Immunotherapeutic Drugs Product Portfolio Table 85. AstraZeneca Recent Development Table 86. Bristol-Mysers Squibb Company Information Table 87. Bristol-Mysers Squibb Business Overview Table 88. Bristol-Mysers Squibb Immunotherapeutic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Bristol-Mysers Squibb Immunotherapeutic Drugs Product Portfolio Table 90. Bristol-Mysers Squibb Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Immunotherapeutic Drugs Product Image Figure 2. Global Immunotherapeutic Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immunotherapeutic Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Immunotherapeutic Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Monoclonal Antibody Image Figure 8. Interferon Image Figure 9. Checkpoint Inhibitor Image Figure 10. Vaccines Image Figure 11. Global Immunotherapeutic Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Immunotherapeutic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Immunotherapeutic Drugs Sales Value Share by Type (2021-2032) Figure 14. Hospitals Image Figure 15. Clinics Image Figure 16. Other Image Figure 17. Global Immunotherapeutic Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Immunotherapeutic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Immunotherapeutic Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Immunotherapeutic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Immunotherapeutic Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Immunotherapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Immunotherapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Immunotherapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Immunotherapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Immunotherapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Immunotherapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Immunotherapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Immunotherapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Immunotherapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Immunotherapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • Interferon
  • Checkpoint Inhibitor
  • Vaccines
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • ELI Lilly
  • GlaxoSmithKline
  • Amgen
  • AbbVie
  • AstraZeneca
  • Bristol-Mysers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Immunotherapeutic Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Immunotherapeutic Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Immunotherapeutic Drugs Market Dynamics
  1. 2.1 Immunotherapeutic Drugs Industry Trends
  2. 2.2 Immunotherapeutic Drugs Industry Drivers
  3. 2.3 Immunotherapeutic Drugs Industry Opportunities and Challenges
  4. 2.4 Immunotherapeutic Drugs Industry Restraints
3 Immunotherapeutic Drugs Market by Company
  1. 3.1 Global Immunotherapeutic Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Immunotherapeutic Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Immunotherapeutic Drugs Company Ranking (2024-2026)
  4. 3.4 Global Immunotherapeutic Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Immunotherapeutic Drugs Company Product Type and Application
  6. 3.6 Global Immunotherapeutic Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Immunotherapeutic Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Immunotherapeutic Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Immunotherapeutic Drugs Market by Type
  1. 4.1 Immunotherapeutic Drugs Type Introduction
  2. 4.1.1 Monoclonal Antibody
  3. 4.1.2 Interferon
  4. 4.1.3 Checkpoint Inhibitor
  5. 4.1.4 Vaccines
  6. 4.2 Global Immunotherapeutic Drugs Sales Value by Type
  7. 4.2.1 Global Immunotherapeutic Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Immunotherapeutic Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Immunotherapeutic Drugs Sales Value Share by Type (2021-2032)
5 Immunotherapeutic Drugs Market by Application
  1. 5.1 Immunotherapeutic Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Immunotherapeutic Drugs Sales Value by Application
  6. 5.2.1 Global Immunotherapeutic Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Immunotherapeutic Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Immunotherapeutic Drugs Sales Value Share by Application (2021-2032)
6 Immunotherapeutic Drugs Regional Value Analysis
  1. 6.1 Global Immunotherapeutic Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immunotherapeutic Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Immunotherapeutic Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Immunotherapeutic Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Immunotherapeutic Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Immunotherapeutic Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Immunotherapeutic Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Immunotherapeutic Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Immunotherapeutic Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Immunotherapeutic Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Immunotherapeutic Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Immunotherapeutic Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Immunotherapeutic Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Immunotherapeutic Drugs Sales Value Share by Country, 2025 VS 2032
7 Immunotherapeutic Drugs Country-level Value Analysis
  1. 7.1 Global Immunotherapeutic Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Immunotherapeutic Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Immunotherapeutic Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Immunotherapeutic Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Immunotherapeutic Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Immunotherapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Immunotherapeutic Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Immunotherapeutic Drugs Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Immunotherapeutic Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Immunotherapeutic Drugs Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Immunotherapeutic Drugs Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 ELI Lilly
  26. 8.5.1 ELI Lilly Company Information
  27. 8.5.2 ELI Lilly Business Overview
  28. 8.5.3 ELI Lilly Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ELI Lilly Immunotherapeutic Drugs Product Portfolio
  30. 8.5.5 ELI Lilly Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Immunotherapeutic Drugs Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Immunotherapeutic Drugs Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 AbbVie
  44. 8.8.1 AbbVie Company Information
  45. 8.8.2 AbbVie Business Overview
  46. 8.8.3 AbbVie Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Immunotherapeutic Drugs Product Portfolio
  48. 8.8.5 AbbVie Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Immunotherapeutic Drugs Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Bristol-Mysers Squibb
  56. 8.10.1 Bristol-Mysers Squibb Company Information
  57. 8.10.2 Bristol-Mysers Squibb Business Overview
  58. 8.10.3 Bristol-Mysers Squibb Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Mysers Squibb Immunotherapeutic Drugs Product Portfolio
  60. 8.10.5 Bristol-Mysers Squibb Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst